Assessment of the clinical and economic impact of advate in prophylactic treatment of hemophilia a patients

Authors

  • Research Center for Health Technology Assessment Institute of Public Health, Sacro Cuore University, Rome, Italy

DOI:

https://doi.org/10.2427/8715

Abstract

The objective of this project has been to develop an HTA on Advate, octocog alfa, third-generation ricombinant factor VIII for the treatment and prophylaxis of bleeding episodes in patients affected by Hemophilia A in order to analyse the product’s potentials and limitations in the context of the epidemiological, clinical, economic and organisational situation in Italy.

Downloads

Published

2012-12-31

Issue

Vol. 9 No. 4 Suppl. 2 (2012)

Section

Articles

How to Cite

Assessment of the clinical and economic impact of advate in prophylactic treatment of hemophilia a patients. (2012). Italian Journal of Public Health, 9(4 Suppl. 2). https://doi.org/10.2427/8715